Combined Use of Gefitinib and Bevacizumab in Advanced Non-Small-Cell Lung Cancer with EGFR G719S/S768I Mutations and Acquired C797S Without T790M After Osimertinib: A Case Report and Literature Review
机构：[1]Department of Respiratory and Critical Care Medicine, Integrated Care Management Center, Institute of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu 610041, China.四川大学华西医院[2]Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science Center for Disease-Related Molecular Network, Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, China.四川大学华西医院[3]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu 610041, China.四川大学华西医院
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective in non-small-cell lung cancer (NSCLC) with sensitizing mutations. However, patients with uncommon EGFR mutations show variable responses, and resistance often develops. The C797S mutation is a common resistance mechanism after third-generation EGFR-TKI osimertinib therapy, with no standard treatment established. A 37-year-old Chinese woman with advanced NSCLC harboring EGFR G719S/S768I mutations developed an acquired C797S mutation without T790M after second- and third-generation EGFR-TKI therapy. She was treated with a combination of gefitinib and bevacizumab, achieving a partial response, particularly in liver metastases. Her overall survival exceeded 60 months. Gefitinib combined with bevacizumab demonstrates efficacy in managing NSCLC with uncommon EGFR mutations and overcoming acquired C797S resistance. This combination therapy offers a promising treatment strategy for patients with limited options after resistance to second- and third-generation EGFR-TKIs.
基金：
This work was supported by the National Natural Science Foundation of China (82470099 to
Y Li, No. 82473213 to P Tian, 92159302 toWLi), Noncommunicable Chronic Diseases-National Science
and Technology Major Project (No. 2024ZD0522806/2024ZD0522800 to P Tian, 2024ZD0522801 to Y
Li, 2024ZD0522806 to W Lu).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
大类|3 区医学
小类|4 区肿瘤学
最新[2025]版：
大类|3 区医学
小类|4 区肿瘤学
第一作者：
第一作者机构：[1]Department of Respiratory and Critical Care Medicine, Integrated Care Management Center, Institute of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu 610041, China.
通讯作者：
通讯机构：[2]Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science Center for Disease-Related Molecular Network, Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, China.[3]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu 610041, China.
推荐引用方式(GB/T 7714)：
Lu Wenting,Sun Jiayi,Jing Yawan,et al.Combined Use of Gefitinib and Bevacizumab in Advanced Non-Small-Cell Lung Cancer with EGFR G719S/S768I Mutations and Acquired C797S Without T790M After Osimertinib: A Case Report and Literature Review[J].Current Oncology (Toronto, Ont.).2025,32(4):doi:10.3390/curroncol32040201.
APA：
Lu Wenting,Sun Jiayi,Jing Yawan,Xu Jing,Huang Chengming...&Li Yalun.(2025).Combined Use of Gefitinib and Bevacizumab in Advanced Non-Small-Cell Lung Cancer with EGFR G719S/S768I Mutations and Acquired C797S Without T790M After Osimertinib: A Case Report and Literature Review.Current Oncology (Toronto, Ont.),32,(4)
MLA：
Lu Wenting,et al."Combined Use of Gefitinib and Bevacizumab in Advanced Non-Small-Cell Lung Cancer with EGFR G719S/S768I Mutations and Acquired C797S Without T790M After Osimertinib: A Case Report and Literature Review".Current Oncology (Toronto, Ont.) 32..4(2025)
